Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Feletti, Alberto;
2024-01-01
Abstract
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41698-024-00506-z.pdf
accesso aperto
Descrizione: CC BY 4.0 publisher version
Tipologia:
Versione dell'editore
Licenza:
Creative commons
Dimensione
11.52 MB
Formato
Adobe PDF
|
11.52 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
